KRT77: A Protein Implicated in Neurodegenerative Disorders (G374454)

Target Name: KRT77

NCBI ID: G374454

KRT77

KRT77: A Protein Implicated in Neurodegenerative Disorders

KRT77, also known as K1B, is a protein that is expressed in the brain and is involved in the regulation of cell death. It has been shown to play a role in various neurological disorders, including Alzheimer's disease, Parkinson's disease, and suicidal behavior. As a result, KRT77 has become a focus of interest for researchers as a potential drug target or biomarker.

The KRT77 protein is a member of the K-type intron splicing proteins (KISP) family. This family of proteins includes several highly conserved proteins that are involved in the regulation of gene expression and cell death. KRT77 is characterized by its 77 amino acid residues and its ability to form a dimeric complex with the protein p53, a well-known regulator of cell death.

KRT77 has been shown to play a role in the regulation of cell death and has been implicated in various neurological disorders. One of the most significant findings related to KRT77 is its role in the development of Alzheimer's disease. Alzheimer's disease is a progressive neurodegenerative disorder that is characterized by the accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain. KRT77 has been shown to be expressed in the brains of individuals with Alzheimer's disease and has been linked to the development of this disease.

In addition to its role in the development of Alzheimer's disease, KRT77 has also been shown to be involved in the regulation of cell death in other neurological disorders, including Parkinson's disease and suicidal behavior. Parkinson's disease is a neurodegenerative disorder that is characterized by the accumulation of Lewy bodies in the brain. KRT77 has been shown to play a role in the regulation of cell death in these disorders and has been linked to the development of these diseases.

The potential drug target for KRT77 is its ability to form a dimeric complex with the protein p53. This interaction between KRT77 and p53 has been shown to play a role in the regulation of cell death and has led to the hypothesis that KRT77 may be a useful drug target for the treatment of neurodegenerative disorders.

In addition to its potential as a drug target, KRT77 has also been shown to be a potential biomarker for the diagnosis and progression of neurodegenerative disorders. The ability of KRT77 to form a dimeric complex with p53 has led to the development of a KRT77-based diagnostic assay that can be used to detect the presence of this protein in brain tissue. This diagnostic assay has the potential to be used as a biomarker for the diagnosis and progression of neurodegenerative disorders.

In conclusion, KRT77 is a protein that has been shown to play a role in the regulation of cell death and is of interest as a potential drug target or biomarker. Its role in the regulation of cell death and its ability to form a dimeric complex with the protein p53 make it a promising target for the development of new treatments for neurodegenerative disorders. Further research is needed to fully understand the role of KRT77 in the regulation of cell death and its potential as a drug target or biomarker.

Protein Name: Keratin 77

The "KRT77 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRT77 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets